Cardiothoracic Surgeon Geoffrey R. Cousins, MD, FACS, left, and Interventional Cardiologist Jason Schott, DO, mark the 100th transcatheter aortic valve replacement procedure performed at Memorial ...
Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms. The company ...
SAN ANTONIO -- The early experience of patients needing cardiac surgery after transcatheter aortic valve replacement (TAVR) has surgeons raising the alarm about the excess risks of these challenging ...
WASHINGTON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating ...
A large-scale international study led by Mount Sinai has yielded the first risk score that can help predict mortality for patients with atrial fibrillation (AFib) who have undergone a successful ...
The first powered randomized trial examining early intervention with transcatheter aortic valve replacement (TAVR) in patients with asymptomatic, severe aortic stenosis (AS) found this strategy to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback